Macrophages as an active tumour-targeting carrier of SN38-nanoparticles for cancer therapy.
Taking advantage of their enhanced permeability and retention (EPR) effect, nanomedicines have been extensively studied for targeted drug delivery to tumour tissues. However, tumour heterogeneity restricts the EPR effect and drug penetration into tumours, and nanoformulations only generate a limited therapeutic improvement in clinical settings. Macrophages have the inherent ability of tumour homing, stealth in blood circulation, and phagocytosis of particles. In this study, we used peritoneal macrophages as carriers for the delivery of SN38 nanoparticles (SN38-NPs) for cancer treatment. SN38-NPs were internalised by macrophages without any obvious effect on viability and migration, and not only induced apoptosis of tumour cells in vitro, but also accumulated in tumour tissues in vivo. In addition, the macrophage-based delivery system for SN38-NPs showed improved therapeutic effect than an equivalent dose of CPT-11 in an A549 subcutaneous tumour model.